0001193125-23-138946.txt : 20230509 0001193125-23-138946.hdr.sgml : 20230509 20230509081320 ACCESSION NUMBER: 0001193125-23-138946 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20230509 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20230509 DATE AS OF CHANGE: 20230509 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Verrica Pharmaceuticals Inc. CENTRAL INDEX KEY: 0001660334 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 463137900 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-38529 FILM NUMBER: 23900085 BUSINESS ADDRESS: STREET 1: 10 NORTH HIGH STREET STREET 2: SUITE 200 CITY: WEST CHESTER STATE: PA ZIP: 19380 BUSINESS PHONE: 484-453-3300 MAIL ADDRESS: STREET 1: 10 NORTH HIGH STREET STREET 2: SUITE 200 CITY: WEST CHESTER STATE: PA ZIP: 19380 8-K 1 d429426d8k.htm 8-K 8-K
false 0001660334 0001660334 2023-05-09 2023-05-09

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): May 9, 2023

 

 

Verrica Pharmaceuticals Inc.

(Exact Name of Registrant as Specified in its Charter)

 

 

 

Delaware   001-38529   46-3137900

(State or Other Jurisdiction

of Incorporation)

  

(Commission

File Number)

  

(IRS Employer

Identification No.)

 

44 W. Gay St., Suite

400 West Chester, PA

   19380
(Address of Principal Executive Offices)   (Zip Code)

Registrant’s telephone number, including area code: (484) 453-3300

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Securities Exchange Act of 1934:

 

Title of each class

  

Trading

symbol

  

Name of each exchange

on which registered

Common Stock   VRCA   The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company  ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☒

 

 

 

Item 2.02

Results of Operations and Financial Condition.

On May 9, 2023, Verrica Pharmaceuticals Inc. (the “Registrant”) issued a press release announcing its financial results for the quarter ended March 31, 2023. This press release has been furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

In accordance with General Instruction B.2. of Form 8-K, the information in this Item 2.02, and Exhibit 99.1 hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liability of that section, nor shall it be deemed incorporated by reference in any of the Registrant’s filings under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, regardless of any incorporation language in such a filing, except as expressly set forth by specific reference in such a filing.

 

Item 9.01

Financial Statements and Exhibits.

(d) Exhibits

 

Exhibit

Number

    Exhibit Description
99.1    Press Release, dated May 9, 2023
104    Cover Page Interactive Data File (formatted as inline XBRL).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

      Verrica Pharmaceuticals Inc.
Date: May 9, 2023      

/s/ P. Terence Kohler Jr.

      P. Terence Kohler Jr.
      Chief Financial Officer
 EX-99.1 2 d429426dex991.htm EX-99.1 EX-99.1

Exhibit 99.1

 

LOGO

Verrica Pharmaceuticals Reports First Quarter 2023 Financial Results

New Drug Application for YCANTH™ (VP-102) PDUFA Goal Date of July 23, 2023 - Potential to Become Only FDA-approved Therapy for Treatment of Molluscum Contagiosum

Raised Gross Proceeds of $32.5 Million in February 2023 in an Underwritten Offering

VP-315 Advanced into Part 2 of Phase 2 Trial in Basal Cell Carcinoma

WEST CHESTER, PA – May 9, 2023 (GLOBE NEWSWIRE) – Verrica Pharmaceuticals Inc. (“Verrica” or “the Company”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced financial results for the first quarter ended March 31, 2023.

“The first quarter of 2023 saw continued execution across our pipeline and strengthening of our financial position,” said Ted White, Verrica’s President and Chief Executive Officer. “With the upcoming PDUFA goal date of July 23, we may be poised to reach a major inflection point with the potential approval of YCANTH™ for the treatment of molluscum contagiosum. Molluscum is a dermatological condition that afflicts millions of children each year in the U.S., and with no FDA approved therapies, we believe YCANTH™ has the potential to address this significant unmet medical need. We also made progress with our novel oncolytic peptide, VP-315, which advanced into the second part of our ongoing Phase 2 study in basal cell carcinoma in April 2023 following a positive safety assessment and promising signs of activity from Part 1 of the study.

“We also had the opportunity to strengthen our balance sheet during the quarter, raising an additional $32.5 million in gross proceeds in an underwritten offering to further extend our cash runway. This additional capital will help support our pre-commercial activities for YCANTH™ and fund our ongoing VP-315 Phase 2 study. Looking ahead, we are excited about the progress we expect to make throughout the remainder of the year.”

Business Highlights and Recent Developments

VP-102

 

  •  

On February 27, 2023, the U.S. Food and Drug Administration (FDA) assigned a Prescription Drug User Fee Act (PDUFA) of July 23, 2023, for Verrica’s New Drug Application (NDA) for YCANTH™ (VP-102), which is being developed for the treatment of molluscum contagiosum (molluscum).

  •  

On January 4, 2023, Verrica announced the successful completion of the technology transfer of bulk solution manufacturing of YCANTH to Piramal Pharma Solutions. The technology transfer includes the completion of the registration batch material, which has been placed on stability, and the manufacture of three process validation batches of bulk solution.

VP-315

 

  •  

On April 12, 2023, Verrica announced that the first patient has been dosed in Part 2 of a Phase 2 study evaluating the Company’s potentially first-in-class oncolytic peptide, VP-315, for the treatment of basal cell carcinoma. Part 2 of the Phase 2 trial is designed to further explore dosing regimens to identify the recommended dose for Part 3 of the study, which is expected to start in the first half of 2024.

Underwritten Offering

 

  •  

On February 21, 2023, the Company announced the pricing of a $32.5 million underwritten offering of common stock and pre-funded warrants.

Financial Results

First Quarter 2023 Financial Results

 

  •  

Verrica recognized collaboration revenues of $37,000 in the first quarter of 2023 compared to $0.4 million for the same period in 2022 related to the Collaboration and License Agreement with Torii Pharmaceutical Col, Ltd (“Torii”). The collaboration revenue consists of supplies and development activity with Torii.

 

  •  

Research and development expenses were $2.7 million in the first quarter of 2023, compared to $2.4 million for the same period in 2022. The increase was primarily attributable to additional CMC costs related to our development of VP-102 for molluscum.

 

  •  

General and administrative expenses were $4.3 million in the first quarter of 2023, compared to $5.1 million for the same period in 2022. The decrease was primarily related to lower compensation costs due to a reduction in headcount.

 

  •  

Costs of collaboration revenue were $68,000 for the first quarter of 2023, compared to $0.3 million for the same period in 2022. The decrease of $0.2 million was primarily due to less manufacturing supply required to support development and testing services pursuant to the Torii Clinical Supply Agreement.

 

  •  

For the first quarter of 2023, net loss on a GAAP basis was $6.6 million, or $0.15 per share, compared to a net loss of $8.5 million, or $0.31 per share, for the same period in 2022.

 

  •  

For the first quarter of 2023, non-GAAP net loss was $5.5 million, or $0.13 per share, compared to a non-GAAP net loss of $6.8 million, or $0.25 per share, for the same period in 2022.

 

  •  

As of March 31, 2023, Verrica had aggregate cash and cash equivalents of $60.0 million. The Company believes that its existing cash and cash equivalents as of March 31, 2023, will be sufficient to support planned operations into the first quarter of 2024.

Non-GAAP Financial Measures

In evaluating the operating performance of its business, Verrica’s management considers non-GAAP loss from operations, non-GAAP net loss and non-GAAP net loss per share. These non-GAAP financial measures exclude stock-based compensation charges and non-cash interest expense that are required by GAAP. Verrica believes that non-GAAP loss from operations, non-GAAP net loss and non-GAAP net loss per share provides useful information to both management and investors by excluding the effect of certain non-cash expenses and items that Verrica believes may not be indicative of its operating performance, because either they are unusual and Verrica does not expect them to recur in the ordinary course of its business, or they are unrelated to the ongoing operation of the business in the ordinary course. Non-GAAP loss from operations, non-GAAP net loss and non-GAAP net loss per share should be considered in addition to results prepared in accordance with GAAP, but should not be considered a substitute for, or superior to, GAAP results. Non-GAAP loss from operations, non-GAAP net loss and non-GAAP net loss per share have been reconciled to the nearest GAAP measure in the tables following the financial statements in this press release.

About YCANTH™ (VP-102)

YCANTH™ (VP-102) is a proprietary drug-device combination product that contains a GMP-controlled formulation of cantharidin delivered via a single-use applicator that allows for precise topical dosing and targeted administration for the treatment of molluscum. If approved, YCANTH™ would be the only product approved by the FDA to treat molluscum — a common, highly contagious skin disease that affects an estimated six million people in the United States, primarily children. In addition, Verrica has successfully completed a Phase 2 study of VP-102 for the treatment of common warts and a Phase 2 study of VP-102 for the treatment of external genital warts.

About VP-315

VP-315 is a potentially first-in-class oncolytic peptide immunotherapy in development as a non-surgical treatment option for non-melanoma skin cancers. The Phase 2 trial is a three-part, open-label, multicenter, dose-escalation, proof-of-concept study with a safety run-in designed to assess the safety, pharmacokinetics, and efficacy of VP-315 when administered intratumorally to adults with biopsy-proven basal cell carcinoma. The study is expected to enroll approximately 66 adult subjects with a histological diagnosis of basal cell carcinoma in at least one eligible target lesion.

Forward-Looking Statements

Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements may be identified by words such as “believe,” “expect,” “may,” “plan,” “potential,” “will,” and similar expressions, and are based on Verrica’s current beliefs and expectations. These forward-looking statements include expectations regarding the

approval of VP-102 for the treatment of molluscum, the timing of clinical trial completion for VP-315 and Verrica’s cash and cash equivalents being sufficient to support planned operations into the first quarter of 2024. These statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements. Risks and uncertainties that may cause actual results to differ materially include uncertainties inherent in the drug development process and the regulatory approval process, Verrica’s reliance on third parties over which it may not always have full control and uncertainties that are described in Verrica’s Annual Report on Form 10-K for the year ended December 31, 2022 and other filings Verrica makes with the U.S. Securities and Exchange Commission. Any forward-looking statements speak only as of the date of this press release and are based on information available to Verrica as of the date of this release, and Verrica assumes no obligation to, and does not intend to, update any forward-looking statements, whether as a result of new information, future events or otherwise.

VERRICA PHARMACEUTICALS INC.

Statements of Operations

(in thousands, except share and per share data)

 

     Three Months Ended March 31,  
     2023     2022  

Collaboration revenue

    $ 37     $ 431  

Operating expenses:

     

Research and development

      2,739       2,445  

General and administrative

      4,319       5,118  

Cost of collaboration revenue

      68       278  
  

 

 

    

 

 

  

Total expenses

      7,126       7,841  
  

 

 

    

 

 

  

Loss from operations

      (7,089 )      (7,410 ) 

Interest income

      500       22  

Interest and other expense

      —         (1,082 ) 
  

 

 

    

 

 

  

Net loss

    $ (6,589 )    $ (8,470 ) 
  

 

 

    

 

 

  

Net loss per share, basic and diluted

    $ (0.15 )    $ (0.31 ) 
  

 

 

    

 

 

  

Weighted average common shares outstanding, basic and diluted

      43,023,379       27,519,053  
  

 

 

    

 

 

  

VERRICA PHARMACEUTICALS INC.

Selected Balance Sheet Data

(in thousands)

 

     March 31,
2023		      December 31,
2022		  

Cash and cash equivalents

    $ 59,952      $ 34,273  

Receivables, prepaid expenses and other assets

      3,145        4,842  
  

 

 

     

 

 

  

Total current assets

      63,097        39,115  

PP&E, lease right of use asset, other

      5,542        5,606  
  

 

 

     

 

 

  

Total assets

    $ 68,639      $ 44,721  
  

 

 

     

 

 

  

Total liabilities

      3,793        4,688  

Total stockholders’ equity

      64,846        40,033  
  

 

 

     

 

 

  

Total

    $ 68,639      $ 44,721  
  

 

 

     

 

 

  

VERRICA PHARMACEUTICALS INC.

Reconciliation of Non-GAAP Financial Measures (unaudited)

(in thousands except per share data)

 

     Three Months Ended March 31, 2023  
     Loss from
Operations		     Net loss     Net loss per
share		  

GAAP

    $ (7,089 )    $ (6,589 )    $ (0.15 ) 

Non-GAAP Adjustments:

       

Stock-based compensation –

Selling, General & Admin (a)

      836       836    

Stock-based compensation –

Research & Development (a)

      258       258    
  

 

 

    

 

 

    

 

 

  

Adjusted

    $ (5,995 )    $ (5,495 )    $ (0.13 ) 
  

 

 

    

 

 

    

 

 

  
     Three Months Ended March 31, 2022  
     Loss from
Operations		     Net loss     Net loss per
share		  

GAAP

    $ (7,410 )    $ (8,470 )    $ (0.31 ) 

Non-GAAP Adjustments:

       

Stock-based compensation –

Selling, General & Admin (a)

      899       899    

Stock-based compensation –

Research & Development (a)

      417       417    

Non-cash interest expense (b)

        354    
  

 

 

    

 

 

    

 

 

  

Adjusted

    $ (6,094 )    $ (6,800 )    $ (0.25 ) 
  

 

 

    

 

 

    

 

 

  

 

(a)

The effects of non-cash stock-based compensation are excluded because of varying available valuation methodologies and subjective assumptions. Verrica believes this is a useful measure for investors because such exclusion facilitates comparison to peer companies who also provide similar non-GAAP disclosures and is reflective of how management internally manages the business.

(b)

The effects of non-cash interest charges are excluded. Verrica believes such exclusion facilitates an understanding of the effects of the debt service obligations on the Company’s liquidity and comparisons to peer group companies and is reflective of how management internally manages the business.

FOR MORE INFORMATION, PLEASE CONTACT:

Investors:

Terry Kohler

Chief Financial Officer

tkohler@verrica.com

Kevin Gardner

LifeSci Advisors

kgardner@lifesciadvisors.com

Chris Calabrese

LifeSci Advisors

ccalabrese@lifesciadvisors.com

EX-101.SCH 3 vrca-20230509.xsd XBRL TAXONOMY EXTENSION SCHEMA 100000 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink EX-101.LAB 4 vrca-20230509_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Cover [Abstract] Amendment Flag Amendment Flag Entity Central Index Key Entity Central Index Key Document Type Document Type Document Period End Date Document Period End Date Entity Registrant Name Entity Registrant Name Entity Incorporation State Country Code Entity Incorporation State Country Code Entity File Number Entity File Number Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Two Entity Address, City or Town Entity Address, City or Town Entity Address, State or Province Entity Address, State or Province Entity Address, Postal Zip Code Entity Address, Postal Zip Code City Area Code City Area Code Local Phone Number Local Phone Number Written Communications Written Communications Soliciting Material Soliciting Material Pre Commencement Tender Offer Pre Commencement Tender Offer Pre Commencement Issuer Tender Offer Pre Commencement Issuer Tender Offer Security 12b Title Security 12b Title Trading Symbol Trading Symbol Security Exchange Name Security Exchange Name Entity Emerging Growth Company Entity Emerging Growth Company Entity Ex Transition Period Entity Ex Transition Period EX-101.PRE 5 vrca-20230509_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 6 g429426g0508224958867.jpg GRAPHIC begin 644 g429426g0508224958867.jpg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end XML 7 R1.htm IDEA: XBRL DOCUMENT v3.23.1
Document and Entity Information
May 09, 2023
Cover [Abstract]  
Amendment Flag false
Entity Central Index Key 0001660334
Document Type 8-K
Document Period End Date May 09, 2023
Entity Registrant Name Verrica Pharmaceuticals Inc.
Entity Incorporation State Country Code DE
Entity File Number 001-38529
Entity Tax Identification Number 46-3137900
Entity Address, Address Line One 44 W. Gay St.
Entity Address, Address Line Two Suite
Entity Address, City or Town 400 West Chester
Entity Address, State or Province PA
Entity Address, Postal Zip Code 19380
City Area Code (484)
Local Phone Number 453-3300
Written Communications false
Soliciting Material false
Pre Commencement Tender Offer false
Pre Commencement Issuer Tender Offer false
Security 12b Title Common Stock
Trading Symbol VRCA
Security Exchange Name NASDAQ
Entity Emerging Growth Company true
Entity Ex Transition Period true
XML 8 d429426d8k_htm.xml IDEA: XBRL DOCUMENT 0001660334 2023-05-09 2023-05-09 false 0001660334 8-K 2023-05-09 Verrica Pharmaceuticals Inc. DE 001-38529 46-3137900 44 W. Gay St. Suite 400 West Chester PA 19380 (484) 453-3300 false false false false Common Stock VRCA NASDAQ true true EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.1 html 1 24 1 false 0 0 false 0 false false R1.htm 100000 - Document - Document and Entity Information Sheet http://www.verrica.com//20230509/taxonomy/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports d429426d8k.htm d429426dex991.htm vrca-20230509.xsd vrca-20230509_lab.xml vrca-20230509_pre.xml http://xbrl.sec.gov/dei/2022 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "d429426d8k.htm": { "axisCustom": 0, "axisStandard": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2022": 24 }, "contextCount": 1, "dts": { "inline": { "local": [ "d429426d8k.htm" ] }, "labelLink": { "local": [ "vrca-20230509_lab.xml" ] }, "presentationLink": { "local": [ "vrca-20230509_pre.xml" ] }, "schema": { "local": [ "vrca-20230509.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd", "https://xbrl.sec.gov/naics/2022/naics-2022.xsd" ] } }, "elementCount": 25, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2022": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 24, "memberCustom": 0, "memberStandard": 0, "nsprefix": "vrca", "nsuri": "http://www.verrica.com/20230509", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "p", "div", "div", "body", "html" ], "baseRef": "d429426d8k.htm", "contextRef": "duration_2023-05-09_to_2023-05-09", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "100000 - Document - Document and Entity Information", "menuCat": "Cover", "order": "1", "role": "http://www.verrica.com//20230509/taxonomy/role/DocumentDocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "p", "div", "div", "body", "html" ], "baseRef": "d429426d8k.htm", "contextRef": "duration_2023-05-09_to_2023-05-09", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.verrica.com//20230509/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.verrica.com//20230509/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]", "terseLabel": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2022", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.verrica.com//20230509/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.verrica.com//20230509/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.verrica.com//20230509/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two", "terseLabel": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.verrica.com//20230509/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.verrica.com//20230509/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.verrica.com//20230509/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.verrica.com//20230509/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.verrica.com//20230509/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.verrica.com//20230509/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Entity Ex Transition Period", "terseLabel": "Entity Ex Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.verrica.com//20230509/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.verrica.com//20230509/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation State Country Code", "terseLabel": "Entity Incorporation State Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.verrica.com//20230509/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.verrica.com//20230509/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.verrica.com//20230509/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.verrica.com//20230509/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre Commencement Issuer Tender Offer", "terseLabel": "Pre Commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.verrica.com//20230509/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre Commencement Tender Offer", "terseLabel": "Pre Commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.verrica.com//20230509/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Security 12b Title", "terseLabel": "Security 12b Title" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.verrica.com//20230509/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.verrica.com//20230509/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material", "terseLabel": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.verrica.com//20230509/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.verrica.com//20230509/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications", "terseLabel": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.verrica.com//20230509/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r7": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2", "role": "http://www.xbrl.org/2003/role/presentationRef" } }, "version": "2.2" } ZIP 15 0001193125-23-138946-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001193125-23-138946-xbrl.zip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